Printer Friendly

KODAK TO RECEIVE PATENT FOR PCR DEVICE FOR DNA DIAGNOSTICS IN HOSPITAL LABORATORIES

 NEW YORK, July 12 /PRNewswire/-- Eastman Kodak Company (NYSE: EK) has been notified that the U.S. Patent and Trademark Office will issue a patent covering Kodak's method of performing polymerase chain reaction (PCR) diagnosis. This method uses a containment device and will allow clinical laboratories to routinely conduct tests based on PCR technology.
 PCR technology allows very small quantities of DNA to be reproduced into quantities large enough to be detected and interpreted. It shows great promise in the early detection of cancer, infectious and genetic diseases. It can also be used to develop clear evidence in situations where the identification of human tissue is important, such as in assault and paternity disputes.
 Kodak made the announcement at the annual meeting of the American Association of Clinical Chemists. It comes just a few weeks after Kodak, Hoffmann-La Roche Inc. and Chiron Corporation announced they had reached an agreement regarding the rights to PCR technology, ending a dispute among the three companies related to ownership and rights under PCR patents.
 Kodak's PCR method is simple, convenient, and easy to use. It dramatically shortens the time required to produce millions of copies of a single, targeted DNA sequence. In addition, it reduces the potential for false-positive results.
 Kodak became involved in PCR research through a collaborative research and development program with Cetus, Inc. in effect from 1986 through 1989. Since then, Kodak has been actively involved in the development of PCR technology for clinical applications.
 -0- 7/12/93
 /CONTACT: Ronald C. Roberts, media relations, Eastman Kodak Company, 716-724-4513/
 (EK)


CO: Eastman Kodak Company ST: New York IN: CHM MTC SU: PDT

BM -- CL005 -- 0447 07/12/93 13:01 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 12, 1993
Words:280
Previous Article:HUMANA AND GROUP HEALTH ASSOCIATION SIGN LETTER OF INTENT
Next Article:CONMED ACQUIRES ANDOVER MEDICAL, INC., A SUBSIDIARY OF MEDTRONIC, INC.
Topics:


Related Articles
New test homes in on evasive Lyme disease.
KODAK, HOFFMANN-LA ROCHE AND CHIRON
GULL LABORATORIES ANNOUNCES XTRAX(TM) DNA ISOLATION KIT
Mosaic Technologies Receives Patent For Its Novel PCR-Based Bridge Amplification Process
QIAGEN expands its portfolio of licenses to real-time PCR.
From the benchtop to the courtroom.
Improvement of technical and analytical performance in DNA sequencing by external quality assessment-based molecular training.
External quality assurance program for PCR amplification of genomic DNA: an Italian experience.
Rapid diagnosis of herpes simplex encephalitis using microchip electrophoresis of PCR products.
"Reconstituted" [alpha]-thalassemia genomic samples as positive controls for the molecular diagnostic laboratory.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters